Global Oral Proteins & Peptides Market Size, Trend & Opportunity Analysis Report, by Indication (Acromegaly, Celiac Disease, Chronic Idiopathic Constipation, Enteric Hyperoxaluria, Inflammatory Bowel Disease, Type II Diabetes), Type of Molecule (Protein, Peptide), and Forecast, 2025-2035
Global Oral Proteins & Peptides Market Size, Opportunity Analysis and Forecast, 2025-2035
Market Definition and Introduction
The Global Oral Proteins & Peptides Market is estimated to be worth USD 1.63 billion as of 2024, with projections estimating it to reach USD 12.11 billion by 2035, expanding at a memorable CAGR of 20.00% during the forecast period 2025-2035. The oral formulation delivery of biologics has emerged as a revolutionary modern therapeutic option that affects convenience, compliance, and clinical outcomes in the treatment of chronic diseases. In contrast to classical parenteral routes, oral delivery of proteins and peptides will, in the future, set the stage for a truly patient-centric treatment where painful injections are avoided, thereby improving patient adherence and acceptance of therapies, especially in conditions that require long-term management.
Rapid growth of this field is supported by a simultaneous evolution of the scientific disciplines of drug delivery, biotechnology, and gastrointestinal physiology. An oral delivery of protein is being assisted and espoused by proprietary protein delivery platforms and advanced absorption enhancers, together with an enteric coating. Demand is on a steep increase in conditions such as type II diabetes, acromegaly, and inflammatory bowel diseases, all of which have a growing incidence and unmet therapeutic needs. Front-runners in this process are biotech start-ups and big pharmaceutical companies that have committed huge resources to oral biologic pipelines into existence. Thus, an era of minimally invasive treatment modalities is steadily finding its foothold.
Second change is the evolution of next-generation peptides and proteins with pharmacokinetic profiles to become increasingly targeted and
patient-friendly, where realisation is driving the process. The project's focus on not only on rational molecule design and development but also on formulation development to overcome the challenges posed by the gastrointestinal environment and enzymatic degradation. Backed by a favourable regulatory outlook and breakthrough designations, the oral proteins and peptides market appears poised at the intersection of innovation, accessibility, and enduring therapeutic sustainability.
Recent Developments in the Industry
- In October 2024, Novo Nordisk announced expanded clinical trials for its oral semaglutide formulation aimed at enhancing glycemic control in patients with type II diabetes. The company's strategic investment underscores the growing confidence in orally administered peptides for chronic metabolic conditions.
- In August 2024, Oramed Pharmaceuticals secured regulatory fast-track status from the FDA for its Phase III oral insulin candidate, ORMD-0801. This marks a pivotal move toward reshaping the traditional insulin therapy model and lowering dependency on injectable regimens.
- In January 2023, Rani Therapeutics unveiled positive Phase II data for RT-102, an oral formulation of parathyroid hormone. Leveraging its robotic RaniPill platform, the company demonstrated significant bioavailability improvements, reigniting momentum for peptide delivery innovation.
Market Dynamics
Increasing burden of lifestyle and autoimmune diseases, a more urgent requirement for alternative treatment formats has arisen.
Type II diabetes, inflammatory bowel disease, and celiac disease are among the diseases affecting millions around the globe, creating fertile ground for oral therapeutics. Given the option, today, patients prefer not to resort to painful injections. The general uptake of orally administered biologics refers to this behaviour change. Biopharma players are adopting a more aggressive investment in gastrointestinal-compatible delivery systems and formulation technologies to respond to this behavioural change.
Incentives provided by regulatory authorities, influx of investments, further accelerate clinical development and expansion of pipelines.
The FDA in America and EMA, regulatory pressure is mounting toward oral biologics along with fast-track designation, orphan status, and breakthrough therapy advancement. This would avert clinical pipelines and possibly draw good amounts of venture financing. Both startups and established companies forge alliances or enter licensing agreements to upscale their research and penetration of the high-demand therapeutic field.
Patient-centricity has brought an entirely new outlook toward formulation strategy and market penetration.
Increased patient-centricity by the industries has stimulated innovations in dosage forms, packaging, and ease of administration. Oral therapy provides further benefit not just with convenience but also with psychological comfort, especially cherished by pediatric and geriatric segments. While healthcare moves toward a decentralised model with self-administration at its core, oral delivery platforms would play a pivotal role in attending to the global reach of therapeutics.
Strategic partnerships and licensing agreements are driving competitive market expansion.
Strategic partnerships with biopharmaceutical companies have catalysed innovation but have also shared the perceived commercial risk. Licensing deals that target proprietary delivery technologies and co-development pathways are becoming widespread, enabling promising oral therapeutics to access wider marketing geography and faster commercialisation times.
Attractive Opportunities in the Market
- Oral Insulin Revolution - Rising demand for needle-free diabetes treatment fuels innovation in oral insulin delivery.
- Gastrointestinal Peptide Stability Technologies - Encapsulation, enteric coatings, and pH-responsive systems drive bioavailability enhancements.
- Pipeline Expansion in Inflammatory Diseases - Oral delivery targeting IBD, celiac, and Crohn-s disease opens new therapeutic avenues.
- Strategic Licensing Agreements - Collaborations for oral peptide formulations with delivery technology developers accelerate market entry.
- Regulatory Fast-Track Pathways - Supportive FDA and EMA frameworks incentivise accelerated clinical development and approvals.
- Smart Capsules and Robotic Pills - Advanced delivery mechanisms using microneedles and autonomous capsules redefine oral delivery science.
- Rise of Speciality Biotech Startups - Emerging players with proprietary delivery IPs dominate early-stage innovation and partnering models.
- Oral GLP-1 & PTH Therapies - Metabolic and endocrine-focused oral biologics witness clinical and commercial breakthroughs.
Report Segmentation
By Indication: Acromegaly, Celiac Disease, Chronic Idiopathic Constipation, Enteric Hyperoxaluria, Inflammatory Bowel Disease, Type II Diabetes
By Type of Molecule: Protein, Peptide
By Region: North America (U.S., Canada, Mexico), Europe (UK, Germany, France, Spain, Italy, Spain, Rest of Europe), Asia-Pacific (China, India, Japan, Australia, South Korea, Rest of Asia-Pacific), LAMEA (Brazil, Argentina, UAE, Saudi Arabia (KSA), Africa Rest of Latin America)
Key Market Players: Novo Nordisk A/S, Oramed Pharmaceuticals Inc., Chiasma, Inc. (an Amryt Pharma Company), Entera Bio Ltd., Eli Lilly and Company, Biocon Limited, Pfizer Inc., Rani Therapeutics, Protagonist Therapeutics, Amgen Inc.
Report Aspects
Base Year: 2024
Historic Years: 2022, 2023, 2024
Forecast Period: 2025-2035
Report Pages: 293
Dominating Segments
Peptides segment currently dominates the global oral proteins and peptides landscape due to their relatively smaller molecular size for
improved absorption.
The accelerated adoption of this segment has been especially witnessed in type 2 diabetes and metabolic diseases, with an oral GLP-1 analogue leading the way. Technological advancements further complement the improvements with the development of mucoadhesive tablets and protective carriers that enhance peptide stability against enzymatic degradation, hence safeguarding therapeutic efficacy and fostering wide commercial uptake.
Type II Diabetes Emerges as the Largest Indication Due to High Disease Burden and Patient Preference for Oral Medications
Among indications, type II diabetes accounts for the greatest share of the market due to the rising demand for non-invasive, patient-friendly treatment regimens. With over 500 million people suffering from diabetes across the globe, the burden that daily injections pose on both the healthcare profession and the patients is shifting the focus toward oral therapies, with semaglutide and oral insulin being front-runners. Competitive intensity in this domain is spawning innovations in the design of the molecules and the absorption technologies to foster glycemic control and patient adherence.
Rising Market Interest for Inflammatory Bowel Disease Due to Targeted Gut-Localised Delivery Requirements
IBD-ulcerative colitis and Crohn's disease-represents a high-impact market opportunity for oral biologics due to their localised disease pathology. New oral peptides that can survive intestinal transit and selectively target inflamed tissues are under clinical investigation. The increase in the incidence of disease globally, especially in developed countries, is making IBD a top priority for pharmaceutical companies in their oral biologic pipelines.
Key Takeaways
- Oral Biologics Gain Ground - Rising demand for injectable-free delivery of peptides and proteins fuels R&D.
- Peptides Dominate - Enhanced stability, formulation ease, and wide therapeutic applications drive peptide leadership.
- Type II Diabetes at the Forefront - Patient preference for oral solutions reshapes diabetes care paradigms.
- Bioavailability Solutions Expand - Protease inhibitors, coatings, and smart capsules improve GI survivability.
- Technology-Driven Alliances - Pharma-biotech collaborations catalyse innovation and commercial readiness.
- Fast-Tracked Approvals - Regulatory incentives speed up development for critical and orphan indications.
- Global Demand for Convenience - Oral formats gain favour in paediatrics, geriatrics, and self-care settings.
- Asia-Pacific to See Explosive Growth - Regional diabetes burden and manufacturing capacity accelerate adoption.
- Smart Pills Shape Future - Robotic and programmable pills revolutionise oral protein/peptide delivery methods.
- Chronic Disease Trends Support Market - Ongoing rise in metabolic and autoimmune conditions supports long-term demand.
Regional Insights
North America Leading all Regions in the Global Market for Oral Proteins and Peptides With Strong Pipeline Activity and Patient-Centric
Innovations
North America has the lion's share of the oral proteins and peptides market, where the United States is at the heart of innovation, clinical trials, and regulatory progression. Companies keen on developing oral routes of administration include Oramed and Rani Therapeutics, where the two have developed oral insulins, while Amgen has established its research on oral parathyroid hormones and other peptides aimed at chronic disease burdens. The FDA also facilitates a quicker track for regulatory approval, which makes North America a conducive area for market development.
Europe Locally Engaged in a Strong Market Interface Driven by Innovation on the Delivery Platforms and by Autoimmune Claims
Europe Locally Engaged in a Strong Market Interface Driven by Innovation on the Delivery Platforms and by Autoimmune Claims. Germany, the UK, and Switzerland are strong contributors to investment and partnerships in this market, as well as significant contributors to the efforts of many European nations. The region is already showing a lot of interest in targeting celiac disease and inflammatory bowel disorders through oral peptide technologies. The progressive regulations on biologics by the EMA advanced cross-border growth and technology exchange across the region.
Asia-Pacific to Rapidly Advance Due to the Heavy Disease Burden and Excellent R&D Environment
The fastest growth in the Asia-Pacific region is expected over the entire forecast period and is supported by a high prevalence of diabetes and improving biotechnological infrastructures in India, China, and South Korea. All government healthcare initiatives, in addition to increased investment in devices for drug delivery, make the region a competitive environment for both innovation and mass-scale production.
LATAM and MEA markets register steady growth due to improved access to healthcare and modernisation.
These regions, while still in their infancy, have started integrating oral protein and peptide therapies into their chronic disease management protocols. Investment in increased healthcare awareness and development of medical infrastructure in these regions means that they are still relatively virgin markets yet to capitalise on the potential expansion opportunities in performance, particularly as there is a considerable cost and logistics issue limiting the uptake of these injectable biologics.
Key Benefits for Stakeholders
- The report offers a quantitative assessment of market segments, emerging trends, projections, and market dynamics for the period 2024 to 2035.
- The report presents comprehensive market research, including insights into key growth drivers, challenges, and potential opportunities.
- Porter's Five Forces analysis evaluates the influence of buyers and suppliers, helping stakeholders make strategic, profit-driven decisions and strengthen their supplier-buyer relationships.
- A detailed examination of market segmentation helps identify existing and emerging opportunities.
- Key countries within each region are analysed based on their revenue contributions to the overall market.
- The positioning of market players enables effective benchmarking and provides clarity on their current standing within the industry.
- The report covers regional and global market trends, major players, key segments, application areas, and strategies for market expansion.
Frequently Asked Question(FAQ) :
The shift is primarily driven by the pursuit of patient-centric treatment. Oral delivery improves patient adherence and acceptance by eliminating painful injections, particularly for chronic conditions requiring long-term management. Additionally, the move toward decentralized healthcare and self-administration supports the demand for convenient oral formats.
Type II diabetes is the largest indication due to its high global disease burden (over 500 million people) and the strong patient preference for non-invasive treatments. The development of oral semaglutide and oral insulin candidates has positioned this segment at the forefront of the industry.
Peptides currently lead the market because of their relatively smaller molecular size compared to proteins, which allows for improved absorption. Their dominance is further supported by the successful adoption of oral GLP-1 analogues for metabolic diseases and advancements in mucoadhesive tablets that enhance peptide stability.
The industry is utilizing advanced delivery platforms including enteric coatings, protease inhibitors, pH-responsive systems, and encapsulation. Furthermore, "smart" delivery mechanisms like robotic pills (e.g., RaniPill) and autonomous capsules with microneedles are being developed to ensure biologics survive the harsh gastrointestinal environment.
North America holds the largest market share, centered largely in the United States. This leadership is attributed to a robust R&D pipeline, high clinical trial activity, presence of major players like Amgen and Oramed, and a favorable regulatory environment facilitated by the FDA.
The Asia-Pacific region is anticipated to advance most rapidly. This growth is fueled by a heavy chronic disease burden (particularly diabetes), improving biotechnological infrastructure in India, China, and South Korea, and increased government investment in drug delivery innovation.
Key developments include Novo Nordisk’s expanded trials for oral semaglutide (October 2024), Oramed Pharmaceuticals receiving FDA fast-track status for its Phase III oral insulin candidate ORMD-0801 (August 2024), and Rani Therapeutics reporting positive Phase II data for its oral parathyroid hormone (January 2023).
The primary obstacles include low bioavailability and the inherent instability of large molecules in the gastrointestinal tract. Additionally, the high cost and complexity of formulation, rigorous regulatory scrutiny for novel delivery mechanisms, and technical difficulties in scaled manufacturing pose significant hurdles.
The market features a mix of big pharmaceutical companies and specialized biotech firms, including Novo Nordisk A/S, Oramed Pharmaceuticals Inc., Eli Lilly and Company, Biocon Limited, Pfizer Inc., Rani Therapeutics, Entera Bio Ltd., and Protagonist Therapeutics.
